Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Anik Compes"'
Autor:
Reinhard Büttner, Khosro Hekmat, David Kirsch, Michael Hallek, Birgit Gathof, Jana Fassunke, Asmae Gassa, Hakan Alakus, Sven Borchmann, Carolin Selenz, Mia Lohmann, Hanna Ludwig, Johannes Brägelmann, Philipp Lohneis, Lydia Meder, Julia Mattlener, Sara Breid, Marieke Nill, Amy J. Wisdom, Anik Compes, H. Christian Reinhardt, Roland T. Ullrich
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 10 (2022)
Background Single-agent immunotherapy has shown remarkable efficacy in selected cancer entities and individual patients. However, most patients fail to respond. This is likely due to diverse immunosuppressive mechanisms acting in a concerted way to s
Externí odkaz:
https://doaj.org/article/3195db6b915d4f2596d994cb921be8a5
Autor:
Sven Borchmann, Carolin Selenz, Mia Lohmann, Hanna Ludwig, Asmae Gassa, Johannes Brägelmann, Philipp Lohneis, Lydia Meder, Julia Mattlener, Sara Breid, Marieke Nill, Jana Fassunke, Amy J. Wisdom, Anik Compes, Birgit Gathof, Hakan Alakus, David Kirsch, Khosro Hekmat, Reinhard Büttner, H. Christian Reinhardt, Michael Hallek, Roland T. Ullrich
BackgroundSingle-agent immunotherapy has shown remarkable efficacy in selected cancer entities and individual patients. However, most patients fail to respond. This is likely due to diverse immunosuppressive mechanisms acting in a concerted way to su
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bffce8a9976a1567d1be969cb128ee15
https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&origin=inward&scp=85139753206
https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&origin=inward&scp=85139753206
Autor:
Carolin Selenz, Anik Compes, Marieke Nill, Sven Borchmann, Margarete Odenthal, Alexandra Florin, Johannes Brägelmann, Reinhard Büttner, Lydia Meder, Roland T. Ullrich
Publikováno v:
Cancers; Volume 14; Issue 16; Pages: 3943
EGFR-driven non-small-cell lung cancer (NSCLC) patients are currently treated with TKIs targeting EGFR, such as erlotinib or osimertinib. Despite a promising initial response to TKI treatment, most patients gain resistance to oncogene-targeted therap
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d0ffe3b9b49c0644b905fed26c36f661
https://doi.org/10.3390/cancers14163943
https://doi.org/10.3390/cancers14163943